Our dedicated perfusion bioreactor system redefines traditional fed-batch upstream workflows, enabling fully continuous biomanufacturing for mammalian cell lines, viral vectors and advanced therapy products. Integrated with high-efficiency cell retention devices including alternating tangential flow (ATF) or tangential flow filtration (TFF) modules, the platform continuously replenishes fresh culture medium while draining spent supernatant, retaining viable cells inside the bioreactor for long-duration steady-state cultivation.
Sustained high cell density and prolonged production residence time drastically elevate volumetric productivity and target protein titre, greatly reducing required bioreactor working volume and cleanroom footprint compared to conventional batch and fed-batch processes. Closed automated fluid circulation eliminates manual intervention risks, with real-time closed-loop control of temperature, pH, dissolved oxygen, agitation and perfusion rate to stabilise culture conditions over weeks or even months of continuous operation.
Designed for seamless process scalability and full data integrity, the system supports consistent technology transfer from lab-scale process optimisation to pilot and commercial continuous production lines. It cuts raw material consumption, downstream load and overall manufacturing costs, complies with cGMP and 21 CFR Part 11 requirements, and delivers superior batch-to-batch consistency for monoclonal antibodies, recombinant proteins and viral vector mass production, helping biomanufacturers transition from traditional batch manufacturing to modern continuous bioprocessing platforms.
